Lymphomagenesis in Hodgkin lymphoma

Seminars in Cancer Biology

Volumn 34, Issue , 2015, Pages 14-21

  Matsuki, Eri ^a   Younes, Anas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Classical Hodgkin lymphoma; Hodgkin and Reed Sternberg cells; JAK STAT; Microenvironment; NF B

Indexed keywords

CD30 LIGAND; CD40 LIGAND; EOTAXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN 9; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; RANTES; STAT PROTEIN; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNINDEXED DRUG; CHEMOKINE; CYTOKINE;

AUTOCRINE EFFECT; CARCINOGENESIS; CYTOKINE PRODUCTION; EPIGENETICS; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; LYMPHOMAGENESIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; PARACRINE SIGNALING; REED STERNBERG CELL; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL COMMUNICATION; COMPLICATION; EPSTEIN BARR VIRUS INFECTION; GENETIC EPIGENESIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; CELL COMMUNICATION; CHEMOKINES; CYTOKINES; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84942292736     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.02.002     Document Type: Review

References (121)

1. Hodgkin On some morbid appearances of the absorbent glands and spleen. Med-Chir Trans 1832, 17:68-114.
2. Kuppers R., Engert A., Hansmann M.L. Hodgkin lymphoma. J Clin Investig 2012, 122:3439-3447.
3. Kanzler H., Kuppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996, 184:1495-1505.
4. Marafioti T., Hummel M., Foss H.D., Laumen H., Korbjuhn P., Anagnostopoulos I., et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000, 95:1443-1450.
5. World Health Organization WHO classification of tumours of haematopoietic and lymphoid tissues 2008, International Agency for Research on Cancer, Lyon. 4th ed.
6. Carbone A., Gloghini A., Aldinucci D., Gattei V., Dalla-Favera R., Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol 2002, 117:366-372.
7. Valsami S., Pappa V., Rontogianni D., Kontsioti F., Papageorgiou E., Dervenoulas J., et al. A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4. Haematologica 2007, 92:1343-1350.
8. Kuppers R., Rajewsky K., Zhao M., Simons G., Laumann R., Fischer R., et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 1994, 91:10962-10966.
9. Seitz V., Hummel M., Marafioti T., Anagnostopoulos I., Assaf C., Stein H. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000, 95:3020-3024.
10. Muschen M., Rajewsky K., Brauninger A., Baur A.S., Oudejans J.J., Roers A., et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000, 191:387-394.
11. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Investig 1997, 100:2961-2969.
12. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dorken B., Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999, 18:943-953.
13. Kube D., Holtick U., Vockerodt M., Ahmadi T., Haier B., Behrmann I., et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001, 98:762-770.
14. Skinnider B.F., Elia A.J., Gascoyne R.D., Patterson B., Trumper L., Kapp U., et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002, 99:618-626.
15. Vainchenker W., Constantinescu S.N. JAK/STAT signaling in hematological malignancies. Oncogene 2013, 32:2601-2613.
16. Herbst H., Dallenbach F., Hummel M., Niedobitek G., Pileri S., Muller-Lantzsch N., et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A 1991, 88:4766-4770.
17. Vockerodt M., Yap L.-F., Shannon-Lowe C., Curley H., Wei W., Vrzalikova K., et al. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol 2015, 235:312-322.
18. Flavell J.R., Baumforth K.R., Wood V.H., Davies G.L., Wei W., Reynolds G.M., et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008, 111:292-301.
19. Baumforth K.R., Birgersdotter A., Reynolds G.M., Wei W., Kapatai G., Flavell J.R., et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008, 173:195-204.
20. Kilger E., Kieser A., Baumann M., Hammerschmidt W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998, 17:1700-1709.
21. Young L.S., Dawson C.W., Eliopoulos A.G. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol 2000, 53:238-247.
22. Dawson C.W., Tramountanis G., Eliopoulos A.G., Young L.S. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003, 278:3694-3704.
23. Chaganti S., Bell A.I., Pastor N.B., Milner A.E., Drayson M., Gordon J., et al. Epstein-Barr virus infection in vitro can rescue germinal center B cells with inactivated immunoglobulin genes. Blood 2005, 106:4249-4252.
24. Schwering I., Brauninger A., Klein U., Jungnickel B., Tinguely M., Diehl V., et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 101:1505-1512.
25. Re D., Muschen M., Ahmadi T., Wickenhauser C., Staratschek-Jox A., Holtick U., et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed-Sternberg cells. Cancer Res 2001, 61:2080-2084.
26. Ushmorov A., Leithauser F., Sakk O., Weinhausel A., Popov S.W., Moller P., et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006, 107:2493-2500.
27. Ushmorov A., Ritz O., Hummel M., Leithauser F., Moller P., Stein H., et al. Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression. Blood 2004, 104:3326-3334.
28. Hertel C.B., Zhou X.G., Hamilton-Dutoit S.J., Junker S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002, 21:4908-4920.
29. Mathas S., Janz M., Hummel F., Hummel M., Wollert-Wulf B., Lusatis S., et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol 2006, 7:207-215.
30. Aldinucci D., Celegato M., Borghese C., Colombatti A., Carbone A. IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haematol 2011, 152:182-190.
31. Aldinucci D., Rapana B., Olivo K., Lorenzon D., Gloghini A., Colombatti A., et al. IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol 2010, 148:115-118.
32. Jundt F., Acikgoz O., Kwon S.H., Schwarzer R., Anagnostopoulos I., Wiesner B., et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 2008, 22:1587-1594.
33. Jundt F., Anagnostopoulos I., Forster R., Mathas S., Stein H., Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002, 99:3398-3403.
34. Schwarzer R., Dorken B., Jundt F. Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells. Leukemia 2012, 26:806-813.
35. Renne C., Martin-Subero J.I., Eickernjager M., Hansmann M.L., Kuppers R., Siebert R., et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol 2006, 169:655-664.
36. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
37. Horie R., Watanabe T., Morishita Y., Ito K., Ishida T., Kanegae Y., et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002, 21:2493-2503.
38. Lake A., Shield L.A., Cordano P., Chui D.T., Osborne J., Crae S., et al. Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009, 125:1334-1342.
39. Liu X., Yu H., Yang W., Zhou X., Lu H., Shi D. Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma. Cancer Genet Cytogenet 2010, 197:152-157.
40. Joos S., Menz C.K., Wrobel G., Siebert R., Gesk S., Ohl S., et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002, 99:1381-1387.
41. Martin-Subero J.I., Gesk S., Harder L., Sonoki T., Tucker P.W., Schlegelberger B., et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002, 99:1474-1477.
42. Malynn B.A., Ma A. A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. J Exp Med 2009, 206:977-980.
43. Schmitz R., Hansmann M.L., Bohle V., Martin-Subero J.I., Hartmann S., Mechtersheimer G., et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009, 206:981-989.
44. Saitoh Y., Yamamoto N., Dewan M.Z., Sugimoto H., Martinez Bruyn V.J., Iwasaki Y., et al. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 2008, 111:5118-5129.
45. Otto C., Giefing M., Massow A., Vater I., Gesk S., Schlesner M., et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol 2012, 157:702-708.
46. Ranuncolo S.M., Pittaluga S., Evbuomwan M.O., Jaffe E.S., Lewis B.A. Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 2012, 120:3756-3763.
47. Schmidt A., Schmitz R., Giefing M., Martin-Subero J.I., Gesk S., Vater I., et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer 2010, 49:803-809.
48. Martin-Subero J.I., Wlodarska I., Bastard C., Picquenot J.M., Hoppner J., Giefing M., et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood 2006, 108:401-402. [author reply 2-3].
49. Hinz M., Lemke P., Anagnostopoulos I., Hacker C., Krappmann D., Mathas S., et al. Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002, 196:605-617.
50. Scheeren F.A., Diehl S.A., Smit L.A., Beaumont T., Naspetti M., Bende R.J., et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 2008, 111:4706-4715.
51. Joos S., Kupper M., Ohl S., von Bonin F., Mechtersheimer G., Bentz M., et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000, 60:549-552.
52. Van Roosbroeck K., Cox L., Tousseyn T., Lahortiga I., Gielen O., Cauwelier B., et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011, 117:4056-4064.
53. Weniger M.A., Melzner I., Menz C.K., Wegener S., Bucur A.J., Dorsch K., et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006, 25:2679-2684.
54. Dutton A., Reynolds G.M., Dawson C.W., Young L.S., Murray P.G. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J Pathol 2005, 205:498-506.
55. Georgakis G.V., Li Y., Rassidakis G.Z., Medeiros L.J., Mills G.B., Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006, 132:503-511.
56. Zheng B., Fiumara P., Li Y.V., Georgakis G., Snell V., Younes M., et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 2003, 102:1019-1027.
57. Steidl C., Connors J.M., Gascoyne R.D. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011, 29:1812-1826.
58. Kis L.L., Gerasimcik N., Salamon D., Persson E.K., Nagy N., Klein G., et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 2011, 117:165-174.
59. Kapp U., Yeh W.C., Patterson B., Elia A.J., Kagi D., Ho A., et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999, 189:1939-1946.
60. Chiu A., Xu W., He B., Dillon S.R., Gross J.A., Sievers E., et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007, 109:729-739.
61. Cattaruzza L., Gloghini A., Olivo K., Di Francia R., Lorenzon D., De Filippi R., et al. Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin's lymphoma. Int J Cancer 2009, 125:1092-1101.
62. Aldinucci D., Lorenzon D., Cattaruzza L., Pinto A., Gloghini A., Carbone A., et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer 2008, 122:769-776.
63. Aldinucci D., Gloghini A., Pinto A., Colombatti A., Carbone A. The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. Leuk Lymphoma 2012, 53:195-201.
64. van den Berg A., Visser L., Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999, 154:1685-1691.
65. Jundt F., Anagnostopoulos I., Bommert K., Emmerich F., Muller G., Foss H.D., et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999, 94:2065-2071.
66. Gruss H.J., Brach M.A., Drexler H.G., Bonifer R., Mertelsmann R.H., Herrmann F. Expression of cytokine genes, cytokine receptor genes, and transcription factors in cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992, 52:3353-3360.
67. Skinnider B.F., Mak T.W. The role of cytokines in classical Hodgkin lymphoma. Blood 2002, 99:4283-4297.
68. King R.L., Howard M.T., Bagg A. Hodgkin lymphoma: pathology, pathogenesis, and a plethora of potential prognostic predictors. Adv Anat Pathol 2014, 21:12-25.
69. Poppema S., van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Sem Cancer Biol 2000, 10:345-350.
70. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
71. Aldinucci D., Gloghini A., Pinto A., De Filippi R., Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010, 221:248-263.
72. Tanijiri T., Shimizu T., Uehira K., Yokoi T., Amuro H., Sugimoto H., et al. Hodgkin's Reed-Sternberg cell line (KM-H2) promotes a bidirectional differentiation of CD4+CD25+Foxp3+ T cells and CD4+ cytotoxic T lymphocytes from CD4+ naive T cells. J Leukoc Biol 2007, 82:576-584.
73. Herbst H., Foss H.D., Samol J., Araujo I., Klotzbach H., Krause H., et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996, 87:2918-2929.
74. Kadin M.E., Agnarsson B.A., Ellingsworth L.R., Newcom S.R. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am J Pathol 1990, 136:1209-1214.
75. Juszczynski P., Ouyang J., Monti S., Rodig S.J., Takeyama K., Abramson J., et al. The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007, 104:13134-13139.
76. Ma Y., Visser L., Blokzijl T., Harms G., Atayar C., Poppema S., et al. The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Investig 2008, 88:482-490.
77. Verbeke C.S., Wenthe U., Grobholz R., Zentgraf H. Fas ligand expression in Hodgkin lymphoma. Am J Surg Pathol 2001, 25:388-394.
78. Diepstra A., van Imhoff G.W., Karim-Kos H.E., van den Berg A., te Meerman G.J., Niens M., et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007, 25:3101-3108.
79. Diepstra A., Poppema S., Boot M., Visser L., Nolte I.M., Niens M., et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008, 71:219-226.
80. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-3224.
81. Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
82. Zocchi M.R., Catellani S., Canevali P., Tavella S., Garuti A., Villaggio B., et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. Blood 2012, 119:1479-1489.
83. Glimelius I., Edstrom A., Amini R.M., Fischer M., Nilsson G., Sundstrom C., et al. IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol 2006, 76:278-283.
84. Hanamoto H., Nakayama T., Miyazato H., Takegawa S., Hieshima K., Tatsumi Y., et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004, 164:997-1006.
85. Fischer M., Juremalm M., Olsson N., Backlin C., Sundstrom C., Nilsson K., et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003, 107:197-201.
86. Renne C., Minner S., Kuppers R., Hansmann M.L., Brauninger A. Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. Leuk Res 2008, 32:163-167.
87. Hansen H.P., Engels H.M., Dams M., Paes Leme A.F., Pauletti B.A., Simhadri V.L., et al. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma. J Pathol 2014, 232:405-414.
88. Aldinucci D., Lorenzon D., Olivo K., Rapana B., Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004, 45:1731-1739.
89. Celegato M., Borghese C., Casagrande N., Carbone A., Colombatti A., Aldinucci D. Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts. Leuk Lymphoma 2014, 55:149-159.
90. Celegato M., Borghese C., Umezawa K., Casagrande N., Colombatti A., Carbone A., et al. The NF-kappaB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett 2014, 349:26-34.
91. Cader F.Z., Vockerodt M., Bose S., Nagy E., Brundler M.A., Kearns P., et al. The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1. Blood 2013, 122:4237-4245.
92. Keresztes K., Szollosi Z., Simon Z., Tarkanyi I., Nemes Z., Illes A. Retrospective analysis of the prognostic role of tissue eosinophil and mast cells in Hodgkin's lymphoma. Pathol Oncol Res 2007, 13:237-242.
93. von Wasielewski R., Seth S., Franklin J., Fischer R., Hubner K., Hansmann M.L., et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000, 95:1207-1213.
94. Axdorph U., Porwit-MacDonald A., Grimfors G., Bjorkholm M. Tissue eosinophilia in relation to immunopathological and clinical characteristics in Hodgkin's disease. Leuk Lymphoma 2001, 42:1055-1065.
95. Deau B., Bachy E., Ribrag V., Delarue R., Rubio M.T., Bosq J., et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013, 54:41-45.
96. Kamper P., Bendix K., Hamilton-Dutoit S., Honore B., Nyengaard J.R., d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011, 96:269-276.
97. Touati M., Delage-Corre M., Monteil J., Abraham J., Moreau S., Remenieras L., et al. CD68-positive tumor-associated macrophages predict unfavorable treatment outcomes in classical Hodgkin lymphoma in correlation with interim fluorodeoxyglucose-positron emission tomography assessment. Leuk Lymphoma 2014, 1-10.
98. Klein J.L., Nguyen T.T., Bien-Willner G.A., Chen L., Foyil K.V., Bartlett N.L., et al. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma. Am J Clin Pathol 2014, 141:381-387.
99. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010, 362:875-885.
100. ten Berge R.L., Oudejans J.J., Dukers D.F., Meijer J.W., Ossenkoppele G.J., Meijer C.J. Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001, 15:458-464.
101. Oudejans J.J., Jiwa N.M., Kummer J.A., Ossenkoppele G.J., van Heerde P., Baars J.W., et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997, 89:1376-1382.
102. Alvaro T., Lejeune M., Salvado M.T., Bosch R., Garcia J.F., Jaen J., et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005, 11:1467-1473.
103. Asano N., Oshiro A., Matsuo K., Kagami Y., Ishida F., Suzuki R., et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol 2006, 24:4626-4633.
104. Koreishi A.F., Saenz A.J., Persky D.O., Cui H., Moskowitz A., Moskowitz C.H., et al. The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 2010, 18:206-211.
105. Baur A.S., Meuge-Moraw C., Michel G., Delacretaz F. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998, 32:512-520.
106. Tudor C.S., Distel L.V., Eckhardt J., Hartmann A., Niedobitek G., Buettner M. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol 2013, 44:2475-2486.
107. Greaves P., Clear A., Coutinho R., Wilson A., Matthews J., Owen A., et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2013, 31:256-262.
108. Sauer M., Plutschow A., Jachimowicz R.D., Kleefisch D., Reiners K.S., Ponader S., et al. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013, 88:113-115.
109. Axdorph U., Sjoberg J., Grimfors G., Landgren O., Porwit-MacDonald A., Bjorkholm M. Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease. Ann Oncol 2000, 11:1405-1411.
110. Oki Y., Georgakis G.V., Migone T.S., Kwak L.W., Younes A. Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 2007, 92:269-270.
111. Casasnovas R.O., Mounier N., Brice P., Divine M., Morschhauser F., Gabarre J., et al. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007, 25:1732-1740.
112. Gorschluter M., Bohlen H., Hasenclever D., Diehl V., Tesch H. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995, 6:477-482.
113. Ambrosetti A., Nadali G., Vinante F., Carlini S., Veneri D., Todeschini G., et al. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer 1993, 72:201-206.
114. Marri P.R., Hodge L.S., Maurer M.J., Ziesmer S.C., Slager S.L., Habermann T.M., et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 2013, 19:6812-6819.
115. Christiansen I., Enblad G., Kalkner K.M., Gidlof C., Glimelius B., Totterman T.H. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival. Leuk Lymphoma 1995, 19:243-251.
116. Christiansen I., Sundstrom C., Enblad G., Totterman T.H. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol 1998, 102:701-709.
117. Chetaille B., Bertucci F., Finetti P., Esterni B., Stamatoullas A., Picquenot J.M., et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009, 113:2765-3775.
118. Sanchez-Aguilera A., Montalban C., de la Cueva P., Sanchez-Verde L., Morente M.M., Garcia-Cosio M., et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108:662-668.
119. Scott D.W., Chan F.C., Hong F., Rogic S., Tan K.L., Meissner B., et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 2013, 31:692-700.
120. Sanchez-Espiridion B., Martin-Moreno A.M., Montalban C., Figueroa V., Vega F., Younes A., et al. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol 2013, 162:336-347.
121. Navarro A., Gaya A., Martinez A., Urbano-Ispizua A., Pons A., Balague O., et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008, 111:2825-2832.